John MS Bartlett

Correcting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profiles

Jano I van Hemert, R. Kitchen, J. Bartlett, 2010, BMC Genomics.

Response to mTOR inhibition: activity of eIF4E predicts sensitivity in cell lines and acquired changes in eIF4E regulation in breast cancer

Andrew M Hanby, J. Bartlett, J. Dixon, 2011, Molecular Cancer.

Relative impact of key sources of systematic noise in Affymetrix and Illumina gene-expression microarray experiments

R. Kitchen, J. Bartlett, J. Dixon, 2011, BMC Genomics.

Edinburgh Explorer Nottingham Prognostic Index Plus (NPI+): Validation of a clinical decision making tool in breast cancer in an independent series

David Cameron, Daniele Soria, Jacqueline Stephen, 2015 .

Mammostrat® as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy

Hans Christian Pedersen, D. Ross, B. Ring, 2010, Breast Cancer Research.

Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial

Hein Putter, Christos Markopoulos, Annette Hasenburg, 2011, The Lancet.